NetworkNewsBreaks – Therma Bright Inc.’s (TSX.
Post# of 62
Medical device technology provider Therma Bright (TSX.V: THRM) (OTC: THRBF) this morning announced that it is in the final stages of in vitro testing and awaits the results of the TherOZap(TM) technology against the Zika virus. According to the update, a top research laboratory in Canada is conducting the testing, and Therma Bright expects to report further information as it becomes available. “To date the research lab has done an excellent job following protocol and testing our device with the aim of reporting statistically relevant results,” Therma Bright CEO Rob Fia stated in the news release. “Therma Bright made a number of improvements to the device for this testing and we look forward to reporting the test results of our TherOZap(TM) technology against the Zika in the near future.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer